The current PE ratio of IRWD can't be determined, as the TTM EPS of -$0.2 is negative. Ironwood Pharmaceuticals's last PE ratio on record was 443.0 in December 2024.
The mean historical PE ratio of Ironwood Pharmaceuticals over the last six years is 48.74. Over the past six years, IRWD's PE ratio was at its highest in the Dec 2024 quarter at 443, with a price of $4.43 and an EPS of $0.01. The Dec 2021 quarter recorded the bottom point at 3.58, with a price of $11.66 and an EPS of $3.26.
Maximum annual increase: 206.15% in 2022
Maximum annual decrease: -82.12% in 2020
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 443 | N/A | $4.43 | $0.01 |
2023 | N/A | N/A | $11.44 | -$6.45 |
2022 | 10.96 | 206.15% | $12.39 | $1.13 |
2021 | 3.58 | -78.94% | $11.66 | $3.26 |
2020 | 17 | -82.12% | $11.39 | $0.67 |
2019 | 95.07 | N/A | $13.31 | $0.14 |
2018 | N/A | N/A | $10.36 | -$1.85 |
2017 | N/A | N/A | $14.99 | -$0.78 |
2016 | N/A | N/A | $15.29 | -$0.56 |
2015 | N/A | N/A | $11.59 | -$1 |
2014 | N/A | N/A | $15.32 | -$1.39 |
2013 | N/A | N/A | $11.61 | -$2.35 |
2012 | N/A | N/A | $11.08 | -$0.68 |
2011 | N/A | N/A | $11.97 | -$0.65 |
2010 | N/A | N/A | $10.35 | -$0.59 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | N/A | N/A | $1.47 | -$0.2 |
Dec 2024 | 443 | N/A | $4.43 | $0.01 |
Sep 2024 | N/A | N/A | $4.12 | -$0.02 |
Jun 2024 | 108.67 | N/A | $6.52 | $0.06 |
Mar 2024 | N/A | N/A | $8.71 | -$6.77 |
Dec 2023 | N/A | N/A | $11.44 | -$6.45 |
Sep 2023 | N/A | N/A | $9.63 | -$6.13 |
Jun 2023 | N/A | N/A | $10.64 | -$5.9 |
Mar 2023 | 8.92 | -18.61% | $10.52 | $1.18 |
Dec 2022 | 10.96 | 13.22% | $12.39 | $1.13 |
Sep 2022 | 9.68 | -9.36% | $10.36 | $1.07 |
Jun 2022 | 10.68 | 176.68% | $11.53 | $1.08 |
Mar 2022 | 3.86 | 7.82% | $12.58 | $3.26 |
Dec 2021 | 3.58 | -10.05% | $11.66 | $3.26 |
Sep 2021 | 3.98 | -2.21% | $13.06 | $3.28 |
Stock name | PE ratio | Market cap |
---|---|---|
AZN Astrazeneca plc | 29.04 | $225.93B |
CPIX Cumberland Pharmaceuticals Inc | N/A | $87.07M |
NKTR Nektar Therapeutics | N/A | $123.94M |
IRWD Ironwood Pharmaceuticals Inc | N/A | $98.48M |
The current price to earnings ratio of IRWD can't be calculated, as its EPS of -$0.2 is negative.
Over the last 3 years, the average price to earnings ratio for IRWD stock is 98.65.
Over the last 5 years, the average price to earnings ratio for IRWD stock is 47.58.
In the last six years, the Dec 2024 quarter recorded the highest quarterly PE ratio at 443.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.